{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:27:12Z","timestamp":1785526032558,"version":"3.56.0"},"reference-count":44,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2025,2,12]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Depression in older adults is often undertreated. A 2011 systematic review of treatments for treatment-resistant depression (TRD) in older adults identified one placebo-controlled randomised controlled trial (RCT). We aimed to update this review, synthesising evidence for the effectiveness of treatments for TRD in older people.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched electronic databases (PubMed, Cochrane, Web of Science) from 9 January 2011 through 10 December 2023 (updating our search on 7 January 2024 for RCTs investigating TRD therapies in adults aged \u226555 years, defining treatment resistance as \u22651 unsuccessful treatment. We assessed bias with the Cochrane Risk of Bias (RoB) 2 tool, meta-analysed remission rates and evaluated evidence using GRADE (Grading of Recommendations Assessment, Development, and Evaluation) criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>14 studies (11 newly identified, 3 from previous review) involving 1196 participants (mean age 65.0, male\/female 548\/648) met the inclusion criteria; 10 were placebo controlled and 4 were rated as low RoB. The pooled proportion of participants in intervention arms remitting was 0.35 (17 arms; 95% CI=0.26; 0.45). Relative to placebo, intervention participants were more likely to remit (9 studies; OR 2.42 (95% CI=1.49; 3.92)). Relative to controls, remission rates favoured ketamine (n=3; OR 2.91 (1.11; 7.65)), with a trend towards transcranial magnetic stimulation (TMS) (n=3; 1.99 (0.71; 5.61)), and in single placebo-controlled studies, selegiline, aripiprazole augmentation, pharmacogenetic-guided prescribing (PGP) and cognitive remediation favoured interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We identified weak evidence that ketamine therapy and aripiprazole augmentation, and very weak evidence that TMS, PGP and cognitive remediation increased remission. Lack of evidence regarding routinely prescribed antidepressants and psychosocial treatments is problematic, requiring clinicians to extend evidence from younger populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42023494513.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjment-2024-301324","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T16:35:47Z","timestamp":1741019747000},"page":"e301324","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Effectiveness of pharmacological and non-pharmacological interventions for treatment-resistant depression in older patients: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"28","author":[{"given":"Alice Jane","family":"Larsen","sequence":"first","affiliation":[{"name":"Wolfson Institute of Population Health, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Teobaldi","sequence":"additional","affiliation":[{"name":"Wolfson Institute of Population Health, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario Isabel","family":"Espinoza Jeraldo","sequence":"additional","affiliation":[{"name":"Wolfson Institute of Population Health, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Falkai","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Ludwig-Maximilians University Munich, Munich, Bavaria, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2777-7616","authenticated-orcid":false,"given":"Claudia","family":"Cooper","sequence":"additional","affiliation":[{"name":"Wolfson Institute of Population Health, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"2026010702305873000_28.1.e301324.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.10.041"},{"key":"2026010702305873000_28.1.e301324.2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40266-023-01051-3","article-title":"A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult","volume":"40","author":"Blaszczyk","year":"2023","journal-title":"Drugs Aging"},{"key":"2026010702305873000_28.1.e301324.3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/bjp.2019.193","article-title":"Changing prevalence and treatment of depression among older people over two decades","volume":"216","author":"Arthur","year":"2020","journal-title":"Br J Psychiatry"},{"key":"2026010702305873000_28.1.e301324.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2010.04.020"},{"key":"2026010702305873000_28.1.e301324.5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2174\/1570159X1305151013200032","article-title":"Treatment-resistant Late-life Depression: Challenges and Perspectives","volume":"13","author":"Kn\u00f6chel","year":"2015","journal-title":"Curr Neuropharmacol"},{"key":"2026010702305873000_28.1.e301324.6","unstructured":"Mental health of older adults, Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/mental-health-of-older-adults [Accessed 30 Aug 2024]."},{"key":"2026010702305873000_28.1.e301324.7","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1017\/S0033291722002537","article-title":"Associations between psychological therapy outcomes for depression and incidence of dementia","volume":"53","author":"John","year":"2023","journal-title":"Psychol Med"},{"key":"2026010702305873000_28.1.e301324.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2014.04.003"},{"key":"2026010702305873000_28.1.e301324.9","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-019-2222-4","article-title":"The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study","volume":"19","author":"Jaffe","year":"2019","journal-title":"BMC Psychiatry"},{"key":"2026010702305873000_28.1.e301324.10","unstructured":"Recommendations . NICE; Depression in adults: treatment and management Guidance, 2022. Available: https:\/\/www.nice.org.uk\/guidance\/ng222\/chapter\/Recommendations#further-line-treatment [Accessed 14 Jul 2024]."},{"key":"2026010702305873000_28.1.e301324.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.12.134"},{"key":"2026010702305873000_28.1.e301324.12","unstructured":"Evidence . NICE; Repetitive transcranial magnetic stimulation for depression | Guidance, 2015. Available: https:\/\/www.nice.org.uk\/guidance\/ipg542\/evidence [Accessed 14 Jul 2024]."},{"key":"2026010702305873000_28.1.e301324.13","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10081165"},{"key":"2026010702305873000_28.1.e301324.14","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115581093"},{"key":"2026010702305873000_28.1.e301324.15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/pcn.13349","article-title":"Guidelines for diagnosis and treatment of depression in older adults: A report from the Japanese Society of mood disorders","volume":"76","author":"Baba","year":"2022","journal-title":"Psychiatry Clin Neurosci"},{"key":"2026010702305873000_28.1.e301324.16","doi-asserted-by":"publisher","DOI":"10.1177\/0706743716659276"},{"key":"2026010702305873000_28.1.e301324.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"2026010702305873000_28.1.e301324.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7146.1719"},{"key":"2026010702305873000_28.1.e301324.19","doi-asserted-by":"crossref","first-page":"101484","DOI":"10.1016\/j.cegh.2023.101484","article-title":"Introduction to the GRADE tool for rating certainty in evidence and recommendations","volume":"25","author":"Prasad","year":"2024","journal-title":"Clin Epidemiol Glob Health"},{"key":"2026010702305873000_28.1.e301324.20","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950080019003"},{"key":"2026010702305873000_28.1.e301324.21","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0803"},{"key":"2026010702305873000_28.1.e301324.22","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32817396ae"},{"key":"2026010702305873000_28.1.e301324.23","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1001\/jamapsychiatry.2022.2862","article-title":"Effectiveness of Standard Sequential Bilateral Repetitive Transcranial Magnetic Stimulation vs Bilateral Theta Burst Stimulation in Older Adults With Depression: The FOUR-D Randomized Noninferiority Clinical Trial","volume":"79","author":"Blumberger","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"2026010702305873000_28.1.e301324.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00308-6"},{"key":"2026010702305873000_28.1.e301324.25","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1038\/s41386-018-0121-x","article-title":"Efficacy, tolerability, and cognitive effects of deep transcranial magnetic stimulation for late-life depression: a prospective randomized controlled trial","volume":"43","author":"Kaster","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"2026010702305873000_28.1.e301324.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.10.008"},{"key":"2026010702305873000_28.1.e301324.27","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118760660"},{"key":"2026010702305873000_28.1.e301324.28","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jamapsychiatry.2018.1483","article-title":"Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans: A Randomized Clinical Trial","volume":"75","author":"Yesavage","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"2026010702305873000_28.1.e301324.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-021-01242-9"},{"key":"2026010702305873000_28.1.e301324.30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jagp.2020.05.005","article-title":"Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression","volume":"28","author":"Forester","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"key":"2026010702305873000_28.1.e301324.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2020.05.023"},{"key":"2026010702305873000_28.1.e301324.32","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0803"},{"key":"2026010702305873000_28.1.e301324.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2014.09.026"},{"key":"2026010702305873000_28.1.e301324.34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/JCP.0000000000000988","article-title":"Switching to Imipramine Versus Add-on Mirtazapine in Venlafaxine-Resistant Major Depression: A 10-Week Randomized Open Study","volume":"39","author":"Navarro","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"2026010702305873000_28.1.e301324.35","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jagp.2021.01.005","article-title":"Ketamine for Depression in Older Adults","volume":"29","author":"Subramanian","year":"2021","journal-title":"Am J Geriatr Psychiatry"},{"key":"2026010702305873000_28.1.e301324.36","unstructured":"NICE . 1 Recommendations | Esketamine nasal spray for treatment-resistant depression | Guidance, 2022. Available: https:\/\/www.nice.org.uk\/guidance\/ta854\/chapter\/1-Recommendations [Accessed 3 Sep 2024]."},{"key":"2026010702305873000_28.1.e301324.37","doi-asserted-by":"crossref","first-page":"101531","DOI":"10.1016\/j.arr.2021.101531","article-title":"Transcranial magnetic stimulation (TMS) for geriatric depression","volume":"74","author":"Cappon","year":"2022","journal-title":"Ageing Res Rev"},{"key":"2026010702305873000_28.1.e301324.38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/NDT.S6411","article-title":"Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole","volume":"6","author":"Kohen","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2026010702305873000_28.1.e301324.39","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-024-03031-6","article-title":"Depression clinical trials worldwide: a systematic analysis of the ICTRP and comparison with ClinicalTrials.gov","volume":"14","author":"Namiot","year":"2024","journal-title":"Transl Psychiatry"},{"key":"2026010702305873000_28.1.e301324.40","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13673"},{"key":"2026010702305873000_28.1.e301324.41","unstructured":"Reeves C , Islam A , Gentry T . The state of health and care of older people. 2023."},{"key":"2026010702305873000_28.1.e301324.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.0L107"},{"key":"2026010702305873000_28.1.e301324.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2018.09.004"},{"key":"2026010702305873000_28.1.e301324.44","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1037\/pha0000601","article-title":"Diversity inclusion in clinical trials investigating esketamine for depression: A systematic review","volume":"31","author":"Monahan","year":"2023","journal-title":"Exp Clin Psychopharmacol"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2024-301324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:31:23Z","timestamp":1767781883000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2024-301324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3,3]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/bmjment-2024-301324"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2024-301324","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}